Background. The relative contribution of biologic subtype to locoregional recurrence (LRR) in patients treated with neoadjuvant chemotherapy (NAC), mastectomy, and postmastectomy radiotherapy (PMRT) is not clearly defined. Methods. 233 patients with stages 2 and 3 breast cancer who received NAC, mastectomy, and PMRT between 2000 and 2009 were included: 53 % (n = 123) had HR? (ER or PR?/HER2-), 23 % (n = 53) had HER2? (HER2?/ HR? or HR-), and 24 % (n = 57) had triple-negative (TN) disease (HR-/HER2-). The 5-year LRR rates were estimated by Kaplan-Meier methods. Cox regression analysis was performed to evaluate covariates associated with LRR. Results. The median follow-up period was 62 months. A pathologic complete response (pCR) was seen in 14 % of the patients. The 5-year LRR rate was 8 % for the entire cohort. The LRR rate was 0 % for the patients with a pCR versus 9 % for the patients without a pCR (p = 0.05). TN disease [Hazard ratio (HR) 4.4; p = 0.003] and pathologic node positivity (HR 9.8; p = 0.03) were associated with LRR. Patients with TN disease had a higher LRR rate than patients with HER2? or HR? disease (20 vs. 6 and 4 %; p = 0.005). Among patients without a pCR, TN subtype was associated with increased LRR risk (26 versus 7 % HER? and 4 % HR?; p \ 0.001).
Conclusions.
Patients with TN breast cancer had the highest LRR rate after NAC, mastectomy and PMRT. Whereas no LRR was observed among TN patients with a pCR, TN patients with residual disease had a significantly higher LRR risk. Patients with HR? and HER2? breast cancer had favorable LRR rates regardless of NAC response, likely due to receipt of adjuvant systemic targeted therapies.
Postmastectomy radiation therapy (PMRT) confers a survival benefit for breast cancer patients with positive lymph nodes, as supported by data from randomized trials and a large meta-analysis by the Early Breast Cancer Trialists' Collaborative Group. [1] [2] [3] [4] However, these trials did not routinely assess estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status. In addition, all the chemotherapy was delivered in the adjuvant setting. Despite their historical significance, these trials provide limited information for decision making about PMRT based on breast cancer subtype as well as patterns of locoregional recurrence (LRR) in patients who have received neoadjuvant chemotherapy (NAC).
Multiple studies have determined that the likelihood of achieving a pathologic complete response (pCR) to NAC is associated with breast cancer subtype. Triple-negative (TN) and trastuzumab-treated HER2? breast cancer patients demonstrate the highest rates of pCR. [5] [6] [7] Although pCR is a reliable surrogate for survival, 5, 6, 8 its relationship to LRR is less clearly defined. Other than the post hoc analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18/27 trials, the end point of LRR has not been specifically examined in randomized trials of breast cancer patients treated with NAC. 9 Furthermore, these trials did not include patients treated with PMRT, and only 40 % of the patients had hormone receptor status information, precluding analysis of the impact that biologic subtype and NAC response have on LRR.
Postmastectomy radiation therapy is a standard part of the multidisciplinary management for node-positive breast cancer patients treated with NAC and mastectomy. However, the data on identifying patients who remain at high risk for LRR despite standard local therapies are limited. This study aimed to evaluate the effect of breast cancer subtype and response to NAC on LRR risk.
MATERIALS AND METHODS

Patients
After obtaining approval from the institutional review board, 437 patients with clinical stages 2 and 3 breast cancer who underwent NAC, mastectomy, and PMRT between 2000 and 2009 were identified. After exclusion of patients with inflammatory breast cancer (174 patients), receipt of axillary surgery before NAC (13 patients), missing radiation therapy information (10 patients), and a history of non-skin malignancy (7 patients), 233 women comprised the study population.
The clinical stage at presentation was determined by physical examination and mammogram. Pathologic characteristics and treatment details were obtained from medical records. A pCR was defined as no residual invasive disease in the breast and axillary lymph nodes on pathologic examination. The patients were categorized into three groups: those with hormone receptor-positive disease (HR?: ER? and/or PR?, HER2-), those with HER2? disease (HER2?: HER2?, ER or PR±), and those with TN disease (TN: ER-, PR-, and HER2-).
Treatments
All the patients received NAC consisting of an anthracycline (10 %), taxane (6 %), or both (84 %). Of the HER2? patients, 74 % received trastuzumab, which was routinely offered for tumors larger than 1 cm and for nodepositive HER2? breast cancer beginning in 2004. Before NAC, no patient had a sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND), and abnormal axillary lymph nodes were evaluated by sonogram and fine-needle aspiration. After NAC, all patients underwent mastectomy. Nearly all the patients (99 %) underwent ALND, and two patients (1 %) had only SLNB. The median number of axillary lymph nodes removed for all patients was 17 (range 2-50).
All the patients received PMRT (median dose = 5040 cGy). The indications for PMRT were clinical stage 3 disease irrespective of response to NAC or clinical stage 2 disease with residual disease after NAC. In addition to standard PMRT fields, which included the chest wall and supraclavicular fossa, 91 patients (39 %) received an axillary boost, 47 (20 %) received irradiation of internal mammary lymph nodes, and 33 (14 %) received a mastectomy scar boost. Among the patients with ER? breast cancer, 99 % received anti-estrogen therapy after PMRT, and for the HER2? patients receiving trastuzumab, treatment was continued postoperatively for a total duration of 12 months.
Statistical Analysis
Locoregional recurrence was defined as recurrence in the ipsilateral chest wall or internal mammary, supraclavicular, or axillary lymph nodes identified by biopsy or imaging. Patients who did not have LRR were censored at death or the last follow-up visit, calculated from the date of diagnosis. Disease-free survival (DFS) was defined as time to distant recurrence or LRR. The 5-year overall survival (OS), DFS, and LRR rates were estimated using KaplanMeier methods. Differences in clinicopathologic characteristics between breast cancer subtypes were evaluated by Chi square test. Univariate Cox regression analysis for LRR was performed with the following factors: age, grade, biologic subtype, lymphovascular invasion and extracapsular extension, clinical and pathologic stage, number of pathologic positive lymph nodes, and pCR status. A propensity score-matched analysis was performed to assess the influence of biologic subtype on LRR (TN vs. HR? and HER2?).
RESULTS
Patient Characteristics
The median patient age was 46 years (range 24-81 years). Table 1 (9) 2 (4) 1 (2) 20 (16) Mammary 20 (9) 4 (7) 2 (4) 14 (11) Grade [n (%)]
Moderately differentiated 38 (16) 1 (2) 
Neoadjuvant Chemotherapy Response
In this study, 32 (14 %) patients had a pCR after NAC. Compared with patients who had HR? tumors, patients with TN and HER2? tumors had higher rates of pCR. 
Treatment Outcome
The median follow-up period was 62 months (range 7-161 months), during which time 22 patients had LRR, 83 had distant recurrences, and 85 died. The 5-year DFS and OS rates were 69 % [95 % confidence interval (CI) 60-78 %] and 79 % (95 % CI 74-84 %), respectively. The 5-year LRR rate in the entire cohort was 8 % (95 % CI 2-14 %); 6 patients (27 %) with LRR experienced an isolated first event, and 16 patients (73 %) presented with a simultaneous distant recurrence. Among the 22 patients with LRR, 7 patients had isolated chest wall recurrence, 10 had regional nodal recurrence, and 5 presented with both. Regional recurrence most frequently involved the internal mammary lymph nodes (7 patients), followed by supraclavicular lymph nodes (6 patients) and axillary lymph nodes (4 patients). Table 2 details the radiation fields for each patient with an LRR. Although the internal mammary lymph nodes was the most common nodal failure site, only 1 of the 7 patients with failures at this site had received dedicated internal mammary lymph nodes irradiation.
On univariate analysis, patients with TN tumors [hazard ratio (HR) 4.4; p = 0.003) and those with pathologic nodepositive disease after NAC (ypN?; HR 9.8; p = 0.03) had a higher risk of LRR. After propensity score-matched analysis was used to adjust for differences in patient age, lymphovascular invasion, extracapsular extension, pCR status, clinical and pathologic stage, and number of pathologically positive lymph nodes, TN disease remained a significant risk factor for LRR (HR 3.7; p = 0.008).
The interaction between biologic subtype, pCR, and LRR was explored further. The 5-year LRR rates differed significantly between patients based on biologic subtypes, with LRR experienced by 20 % of the patients with TN disease, 6 % of the patients with HER2? disease, and 4 % of the patients with HR? disease (p = 0.005; Fig. 1a) . No LRR was observed among the 32 patients who had a pCR (13 patients with TN, 11 patients with HER2?, and 8 patients with HR? disease). In contrast, the 5-year LRR rate was 9 % among the 201 patients who failed to achieve a pCR (p = 0.05). Of the patients without a pCR, those with TN tumors had a significantly higher rate of LRR than the patients with HER2? or HR? tumors. As shown in Fig. 1b, 10 of 44 patients with TN breast cancer experienced LRR at 5 years (5-year actuarial rate, 26 %) versus 3 of 42 patients with HER2? disease (7 %) and 4 of 115 patients with HR? disease (4 %; p \ 0.001). Table 3 presents the LRR rates among breast cancer subtypes grouped by response to NAC and extent of pathologic nodal disease. Among the 69 patients with pathologically negative nodes after NAC, the rate of LRR was low among all subtypes, with one LRR among the patients with HR? tumors (19 patients) and no LRR among the patients with TN (29 patients) or HER2? (21 patients failed to achieve a pCR had a higher 5-year LRR rate than the patients with HER2? or HR? breast cancer (26 vs. 7 and 4 %; p \ 0.001). These findings underscore the complex relationship between biologic subtype, response to NAC, and clinical outcomes. Biologic subtype is proven to be an accurate predictor of survival for patients treated with NAC. [5] [6] [7] [8] Less is known about the impact of biologic subtype and NAC response on LRR, resulting in controversy concerning the surgical and radiotherapeutic nodal management of patients receiving NAC. [9] [10] [11] [12] [13] Our results add to a growing body of evidence that biologic subtype and response to NAC predict for LRR in patients with breast cancer. To date, the largest study examining these issues is the Collaborative Trials in Neoadjuvant Breast Cancer 14 analysis, which included 5252 NAC patients (39 % received mastectomy). At 42 months, the 5-year LRR rate was 6.8 % in the entire cohort. On multivariate analysis, TN (HR 4.1; 95 % CI 3.0-5.4) and ypN? disease (HR 2.4; 95 % CI 1.6-3.4) were independent predictors of LRR. Although only one third of mastectomy patients received PMRT, the pooled analysis provides compelling evidence for biologic subtype and residual disease as significant risk factors for LRR.
Other studies examining predictors of LRR in breast cancer patients receiving mastectomy and NAC have been limited by lack of biologic subtype information and variable use of PMRT. In a study of 542 patients who underwent NAC and mastectomy, 15 ER-negative breast cancer was associated with a higher risk of LRR (HR 2.1; p = 0.04). However, HER2 status was not analyzed in the study population, thus limiting its applicability to current practice. Meyers et al. 10 demonstrated a higher LRR rate for patients with TN breast cancer (20 %; p = 0.06) after NAC and mastectomy than for patients with HER2? (7 %) or HR? (5 %) breast cancer. Although 18 % of the patients did not receive PMRT, the authors' findings corroborate the high LRR rate observed among patients with TN disease in our study. Wright et al. 16 found that TN subtype was associated with a higher risk of LRR after NAC and mastectomy compared with the non-TN subtype (HR 8.5; 95 % CI 3.5-20.8). Although these publications support the significance of biologic subtype in predicting LRR, the combined effects of biologic subtype and response to NAC were not elucidated.
One of the first studies to demonstrate a relationship between LRR and biologic subtype in patients receiving NAC was published concerning patients who received breast-conserving therapy. In 2012, Caudle et al. 17 reported on LRR as a function of biologic subtype and pCR in 595 patients who received breast-conserving therapy after NAC. The authors found that TN (HR 5.7; 95 % CI 2.6-112.3), HR-/HER2? (HR 5.7; 95 % CI 2.0-16.3), and the presence of four or more positive lymph nodes (HR 2.9; 95 % CI 1.3-6.6) were associated with higher LRR. The 5-year LRR rate was significantly lower for patients achieving pCR (1 % for patients who had TN tumors with a pCR versus 16 % for patients who had TN tumors without a pCR). Although this study predated the routine use of trastuzumab, it substantiates our finding that pCR status and biologic subtype may serve as a surrogate for LRR risk.
In our study, 46 % of the patients who had TN breast cancer with residual disease in one to three lymph nodes experienced LRR at 5 years, whereas the patients who had one to three positive lymph nodes with HER2? or HR? breast cancer had favorable 5-year LRR rates of 13 and 0 %, respectively (p \ 0.001; Table 3 ). A similar trend was observed in patients with four or more positive lymph nodes. The favorable outcomes seen for patients with HR? and HER2? breast cancer are most likely due to the receipt of ongoing adjuvant anti-estrogen and anti-HER2 therapies. Furthermore, the discrepant outcomes observed between incomplete responders with TN versus other subtypes of breast cancer raises the question of how to tailor axillary treatment for such patients. The ongoing ALLIANCE A011202 trial 18 is designed to elucidate whether radiation alone can provide sufficient regional control for patients with ypN? disease after NAC. Our findings suggest that outcomes with radiation alone may differ by subtype because a high LRR rate was observed among TN patients who had ypN? disease treated with both ALND and radiotherapy in our study, who are the subjects of the ALLIANCE trial.
We observed that the internal mammary lymph nodes was the most common site of isolated regional recurrence. Only one of the seven patients with internal mammary lymph nodes recurrence had received irradiation to this site. These findings suggest that the internal mammary nodes should be routinely targeted among patients receiving nodal irradiation after NAC, particularly in TN breast cancer patients, who have high rates of LRR. The low number of LRR events and the small patient subsets preclude us from concluding whether routine omission of internal mammary lymph nodes irradiation is acceptable for HR? and HER2? breast cancer patients, who had low rates of LRR even in the setting of incomplete response to NAC.
In conclusion, our study provides strong evidence that biology plays a critical role in determining locoregional outcomes for patients receiving NAC. Response to NAC and biologic subtype are predictors of LRR in patients who have received mastectomy and PMRT. The poor responders to NAC with TN breast cancer represent a population at high risk for LRR, and maximal locoregional therapy should be considered for these patients. Furthermore, clinical trials evaluating novel treatment approaches to improve locoregional control, such as concurrent PARP inhibitors or chemotherapy with PMRT, are warranted for these patients. Conversely, the favorable LRR rates for patients with HR ? breast cancer suggest that the extent of locoregional therapy may be limited for such patients, even when pCR is not obtained. Larger studies evaluating clinicopathologic variables on LRR in these favorable-risk subsets will help us determine the appropriate treatments for these patients.
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